Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, September 1998, p. 703-710, Vol. 5, No. 5
Eijkman-Winkler Institute for Microbiology,
Infectious Diseases and Inflammation, Section Vaccines, Utrecht
University Hospital, 3584 CX Utrecht, The
Netherlands,1 and
Wyeth-Lederle
Vaccines and Pediatrics, Rochester, New York
14586-97282
Received 18 December 1997/Returned for modification 9 April
1998/Accepted 9 June 1998
A phagocytosis assay for Streptococcus pneumoniae based
on flow cytometry (FACS) with human polymorphonuclear cells and human complement was developed for the study of human vaccination antisera. Human prevaccination sera already contain high levels of
C-polysaccharide (C-PS) antibodies, which are not protective in humans
but which might give false positive results in a flow-cytometry-based
assay. Cultures of S. pneumoniae grown to log phase on
three consecutive days, followed by heat inactivation, yielded stable
and highly encapsulated strains for serotypes 6A, 6B, 14, 19F, and 23F.
As a result, only serotype-specific antibodies were able to facilitate phagocytosis of these strains, whereas no phagocytosis was observed with antibodies against C-PS or pneumococcal surface proteins. No, or
weak, phagocytosis was observed with human prevaccination sera, whereas
in general, postvaccination antisera facilitated phagocytosis. A highly
significant correlation was observed between enzyme-linked
immunosorbent assay titers and FACS phagocytosis titers
(r = 0.98, P < 0.001) for serotype
23F pneumococci with human vaccination antisera. For all serotypes,
interassay variation was below 10%. Major advantages of this assay
over the classical killing assay are that (i) limited amounts of sera
are required (10 µl per titration curve), (ii) 600 samples can be
processed in one day by one person, and (iii) cells can be fixed and
measurement of the samples can be performed up to 1 week later.
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Use of Highly Encapsulated Streptococcus
pneumoniae Strains in a Flow-Cytometric Assay for Assessment of
the Phagocytic Capacity of Serotype-Specific Antibodies
*
Corresponding author. Mailing address: Eijkman-Winkler
Institute for Microbiology, Infectious Diseases and Inflammation,
Section Vaccines, Utrecht University Hospital, Rm. G04.614,
Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Phone:
31-30-2506533. Fax: 31-30-2541770. E-mail:
W.T.M.Jansen{at}lab.azu.nl.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |